Mostrar el registro sencillo del ítem

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

dc.rights.licenseopenen_US
dc.contributor.authorMATHAIS, S.
dc.contributor.authorMOISSET, X.
dc.contributor.authorPEREIRA, B.
dc.contributor.authorTAITHE, F.
dc.contributor.authorCIRON, J.
dc.contributor.authorLABAUGE, P.
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorDULAU, Cecile
dc.contributor.authorLAPLAUD, D.
dc.contributor.authorDE SEZE, J.
dc.contributor.authorPELLETIER, J.
dc.contributor.authorBERGER, E.
dc.contributor.authorLEBRUN-FRENAY, C.
dc.contributor.authorCASTELNOVO, G.
dc.contributor.authorEDAN, G.
dc.contributor.authorDEFER, G.
dc.contributor.authorVERMERSCH, P.
dc.contributor.authorBOURRE, B.
dc.contributor.authorCAMDESSANCHE, J.-P.
dc.contributor.authorMAGY, L.
dc.contributor.authorGUENNOC, A.-M.
dc.contributor.authorMATHEY, G.
dc.contributor.authorMOREAU, T.
dc.contributor.authorGOUT, O.
dc.contributor.authorHEINZLEF, O.
dc.contributor.authorMAILLART, E.
dc.contributor.authorVUKUSIC, S.
dc.contributor.authorCLAVELOU, P.
dc.date.accessioned2022-04-16T09:44:50Z
dc.date.available2022-04-16T09:44:50Z
dc.date.issued2021-01
dc.identifier.issn1878-7479en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136651
dc.description.abstractEnHigh-dose biotin (HDB) is a therapy used in non-active progressive multiple sclerosis (PMS). Several reports have suggested that HDB treatment may be associated with an increased risk of relapse. We aimed to determine whether HDB increases the risk of clinical relapse in PMS and describe the characteristics of the patients who experience it. We conducted a French, multicenter, retrospective study, comparing a group of PMS patients treated with HDB to a matched control group. Poisson regression was applied to model the specific statistical distribution of the annualized relapse rate (ARR). A propensity score (PS), based on the inverse probability of treatment weighting (IPTW), was used to adjust for indication bias and included the following variables: gender, primary PMS or not, age, EDSS, time since the last relapse, and co-prescription of a DMT. Two thousand six hundred twenty-eight patients treated with HDB and 654 controls were analyzed with a follow-up of 17 ± 8 months. Among them, 148 validated relapses were observed in the group treated with biotin and 38 in the control group (p = 0.62). After adjustment based on the PS, the ARR was 0.044 ± 0.23 for the biotin-treated group and 0.028 ± 0.16 for the control group (p = 0.18). The more relapses there were before biotin, the higher the risk of relapse during treatment, independently from the use of HDB. While the number of relapses reported for patients with no previous inflammatory activity receiving biotin has gradually increased, the present retrospective study is adequately powered to exclude an elevated risk of relapse for patients with PMS treated with HDB.
dc.description.sponsorshipObservatoire Français de la Sclérose en Plaquesen_US
dc.language.isoENen_US
dc.subject.enBiotin
dc.subject.enClinical trials observational study
dc.subject.enProgressive multiple sclerosis
dc.subject.enPropensity score
dc.subject.enRelapse
dc.title.enRelapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s13311-020-00926-2en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed32964402en_US
bordeaux.journalNeurotherapeuticsen_US
bordeaux.page378-386en_US
bordeaux.volume18en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - UMR-S 1215en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDMedDay Pharmaceuticalsen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurotherapeutics&rft.date=2021-01&rft.volume=18&rft.issue=1&rft.spage=378-386&rft.epage=378-386&rft.eissn=1878-7479&rft.issn=1878-7479&rft.au=MATHAIS,%20S.&MOISSET,%20X.&PEREIRA,%20B.&TAITHE,%20F.&CIRON,%20J.&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
MAGENDIE_Neurotherapeutics_202 ...
Tamaño:
795.0Kb
Formato:
PDF
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem